Abstract: The present invention deals with the certain novel esters which are prepared by the reaction of an alcohol and meadowfoam fatty, methyl ester or triglyceride. These materials are useful as cosmetic ingredients where outstanding liquidity, resistance to oxidation, and minimal taste and odor variation are required. This combination of properties make these compounds excellent candidates as additives to personal care products like skin care oils and lipsticks.

Abstract: The present invention deals with the composition of matter and the utilization of certain novel complex esters which are prepared by the reaction of meadowfoam oil, meadowfoam fatty acid or methyl meadowfoamate and multi hydroxy compound like pentaerythritol.

Abstract: Lipid molecules bearing a cationic charge are described. These cationic lipids are useful in the delivery of biomolecules, such as oligonucleotides, nucleic acids, peptides, diagnostic imaging agents, proteins and drug molecules. In the form of liposomes, they can effectively be used for the intracellular delivery of biomolecules for therapeutic or diagnostic purposes.

Abstract: The present invention deals with the application of certain novel esters which are prepared by the reaction of a guerbet alcohol and meadowfoam fatty, methyl ester or triglyceride in personal care applications. These materials are useful as cosmetic ingredients where outstanding liquidity, resistance to oxidation, and minimal taste and odor variation are required. This combination of properties make these compounds excellent candidates as additives to personal care products like skin care oils and lipsticks.

Abstract: A Koch functionalized product which is the reaction product of at least one polymer having a number average molecular weight of at least 500 and at least ethylenic double bond per polymer chain, with carbon monoxide and a nucleophilic trapping agent. The invention includes functionalized polymer, derivatives thereof and methods of making the same.

Abstract: There is disclosed structured lipid containing either a gamma-linolenic acid or a dihomogamma-linolenic acid residue, together with an n-3 fatty acid residue and a medium chain fatty acid residue on the same glycerol backbone. This structured lipid is particularly well adapted to the treatment of disease or stress states. The gamma-linolenic or dihomogamma-linolenic acid residues modify the prostanoid synthesis pathway, reducing the level of series "2" prostanoids and elevating the levels of series "1" and "3" prostanoids. The n-3 fatty acid residue enhances the level of series "1" prostanoids as well as increases the production of series "3" prostanoids. The medium chain fatty acid residues enhances the absorption of the structured lipid. There is also disclosed enteral and parenteral diets as well as nutritional supplements containing the structured lipids of the invention.

Abstract: Water or lipid soluble, pharmacologically active, antioxidant, anti-phospholipase compounds that are chemically defined. The compounds protect mammalian cells by inhibiting PLA.sub.2 and preventing oxidation. In particular, each compound has at least two fatty moieties and no active hydroxy group. The compound may also have at least one ionizable group, which may be a carboxyl group, and each of the fatty moieties has from sixteen to twenty carbon atoms and at least one cis-unsaturated double bond.

Abstract: The present invention deals with the certain novel esters which are prepared by the reaction of a guerbet alcohol and meadowfoam fatty, methyl ester or triglyceride. These materials are useful as cosmetic ingredients where outstanding liquidity, resistance to oxidation, and minimal taste and odor variation are required. This combination of properties make these compounds excellent candidates as additives to personal care products like skin care oils and lipsticks.

Abstract: Described are 3,5-dimethyl-pentenyl-dihydro-2(3H)-furanone isomer mixtures defined according to the structure: ##STR1## wherein structure represents mixtures wherein in the mixture in each of the compounds, one of the dashed lines represents a carbon-carbon double bond and the other of the dashed lines represents a carbon-carbon single bond, processes for preparing same and uses thereof in augmenting or enhancing the aroma of consumable materials including perfume compositions, colognes and perfumed articles (e.g., solid or liquid anionic, cationic, nonionic or zwitterionic detergents, hair preparations, fabric softeners, fabric softener articles, cosmetic powders and perfumed polymers). Also described is a process for preparing such 3,5-dimethyl-pentenyl-dihydro-2(3H)-furanone isomer mixtures using as a starting material 2,7-octadienol having the structure: ##STR2## as well as the process intermediates having the structures: ##STR3## wherein R represents C.sub.1 -C.sub.4 alkyl; R.sub.1 and R.sub.

Abstract: In the method of the invention to obtain lipids with a high proportion of long-chain polyunsaturated fatty acids (LCPs) with 20 to 22 carbon atoms by extraction from a raw material of animal or vegetable origin, unicellular algae (microalgae), macroalgae from the families of the brown, red and green algae and/or residues of alginate or carrageenin production with a water content of .ltoreq.50 weight % and a particle size of .ltoreq.50 mm are used. For extraction, an organic solvent or a compressed gas is used. A lipid extract with a high proportion of w6 LCP and w3 LCP and in particular with a content of at least 5 weight % of arachidonic acid and/or a content of at least 3 weight % of docosahexanoic acid is also prepared.

Abstract: Methods for the synthesis of 9-cis monotritium-labeled retinoids, and their use in the discovery of Retinoid X Receptor ligands are provided. In addition, 9-cis monotritium-labeled retinoids, as well as novel intermediates and tritium-labeled intermediates formed during the synthesis of 9-cis monotritium-labeled retinoids are also provided.

Abstract: The invention describes a method for normalizing a cardiac inotropic irregularity, via administering an effective amount of 12(R)HETE. Also described are therapeutic compositions which combine a cardiac glycoside and 12(R)HETE.

Abstract: Sunflower seed, plants and oil are described which have a total level of saturated fatty acids equal to 6% or less relative to the total fatty acid content, a total level of stearic acid less than 1% of the total fatty acid content, and a total level of palmitic acid less than 3% of the total fatty acid content.

Abstract: Fumaric acid derivatives of the formula ##STR1## wherein R.sub.1 is a hydrogen atom, a C.sub.1 -C.sub.8 alkyl group or a metallic cation, andR.sub.2 is a saturated or unsaturated aliphatic C.sub.6 -C.sub.24 alkyl group, psoralen-9-yl, retinyl, .alpha.-tocopheryl (vitamin E), calciferyl, corticosteroid-21-yl or monosaccharid-.omega.-yl; a group of fumaric acid derivatives based on glycerol, alkane diol or polyol molecules; and fumaric acid derivatives of the formula ##STR2## wherein n is an integer from to 30 to 260,R.sub.3 is a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group,R.sub.4 is one of the R.sub.3 groups and n is the number of molecule repetitions, processes for their production and compositions containing same are described. These compounds are useful as drugs for the treatment of cryptogenically-caused diseases and have antisporiatic as well as antimicrobial action.

Abstract: Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. These small molecules are useful for treating vasoconstrictive, inflammatory, myeloid suppressive, cardiovascular, and gastrointestinal diseases.

Abstract: Improved rape plants, seeds capable of forming the same, and a novel improved edible endogenous vegetable oil derived from the rapeseeds are provided. Such plants have the ability to yield an endogenous vegetable oil having an unusually low saturated fatty acid content. More specifically, the rape plants upon self-pollination are capable of forming rapeseeds which yield an improved vegetable oil following crushing and extraction having a saturated fatty acid content of no more than 4 percent by weight (preferably no more than 3.5 percent by weight and most preferably less than 3 percent by weight) in the form of stearic and palmitic acids based upon the total fatty acid content. A relatively low concentration of erucic acid (as described) also is exhibited in the endogenous oil. It has been found that the novel rape plants of the present invention can be formed by mutagenesis followed by selection as described.

Abstract: This specification provides a polymeric material useful for manufacturing contact lenses having improved oxygen permeability. The contact lenses prepared from the polymeric material of the invention show improved hydrophilicity and enhanced oxygen permeability as compared with that made of the conventional fluoroalkyl-containing polymeric materials.

Abstract: Disclosed are a novel class of anti-androgenic compounds including saturated and unsaturated fatty acids, their derivatives, and synthetic analogs, according to the following formula:CH.sub.3 --(CH.sub.2).sub.a --(CR.sub.1 R.sub.2 CH.dbd.CH).sub.b --(CH.sub.2).sub.c --COOH,wherein R.sub.1 and R.sub.2 are each either hydrogen or a halogen; wherein a and c are integers from 0-9; wherein b is an integer from 1-6, provided that12<a+c+(3.times.b).ltoreq.22.Also disclose are methods of synthesis of these compounds, and their use in treating disorders associated with androgenic activities. Also disclosed is the use of known compounds not previously known for their anti-androgenic activity in treating disorders related to androgenic activities.

Abstract: A process for the production of hydroxy fatty acids and novel estolide compounds, each of which may be used as lubricants, greases, plasticizers and printing inks, as well as in cosmetics. The estolides are of the formula (I): ##STR1## wherein R.sub.1 is selected from C.sub.6 -C.sub.16 hydrocarbons which may be saturated or unsaturated, and branched or straight chain, and optionally substituted, such as with one or more hydroxy groups; R.sub.2 is independently selected from C.sub.2 -C.sub.17 hydrocarbons which may be saturated or unsaturated, and branched or straight chain, and optionally substituted, such as with one or more hydroxy groups; A is selected from C.sub.3 -C.sub.14 hydrocarbons which may be saturated or unsaturated, and branched or straight chain, and optionally substituted; n is greater than or equal to 1; y is an integer from 3-13; x is 1 or 2; and . . . designates a single or double carbon/carbon bond.

Abstract: Novel ketone monomers containing both alpha-beta unsaturated acylate and unsaturated fatty acylate substituents on more carbon atoms beta to the carbonyl group (Formula 1) have been found to be surprisingly useful in a variety of essentially pollution free coatings applications.a,b,cCC(0)Cd,e,f Formula IWherein not less than one, but no more than three of a,b,d and e are each independently chosen from among monovalent ligands having the structure --CH.sub.2,O.sub.2 CCR.dbd.CR'R" (wherein each of R,R', and R" is independently chosen from among hydrogen, methyl or ethyl ligands); and wherein at least one, but not more than three of a,b,d and e are each independently chosen from among monovalent ligands having the structure: --CH.sub.2 O.sub.2 CC.sub.n H.sub.

Abstract: A new class of synthetic triglycerides, those having at least one short-chain (C.sub.2 -C.sub.5) fatty acid on a glycerol backbone, has been developed. These synthetic triglycerides (or structured lipids) are particularly useful in treating patients with intestinal problems.

Abstract: A botulinum toxin neutralizer comprising at least one fatty acid having the number of carbon atoms of at least 12. Such a fatty acid may be any of saturated fatty acids such as lauric acid, myristic acid, palmitic acid, stearic acid, nonadecanoic acid, arachidic acid, and behenic acid or any of unsaturated fatty acids such as oleic acid. The toxin neutralizer acts as if it were an antagonistic receptor for botulinum toxin and, when encountering botulinum toxin in human body, directly combines with the toxin and disables the toxin from combining with the neuromuscular tissues of human body to prevent the outbreak of botulism. The toxin thus neutralized and affixed to the botulinum toxin neutralizer is excreted from the human body. The botulinum toxin neutralizer can be manufactured easily and economically from a naturally occurring glyceride and is thus far less costly then the known antitoxin of ganglioside GT1b produced from bovine brain.

Abstract: The present invention relates to a series of novel quaternary polymers and an intermediate useful in it's preparation. The compounds of the present invention are prepared by the reaction of chloracetic acid with a pendant hydroxyl group which is present on a polyoxyalkylene polymer, followed by the reaction of the halo-ester with a tertiary amine to give a quaternary compound. In a preferred embodiment the polyoxyalkylene glycol has been prepared by the reaction of both ethylene oxide and propylene oxide. In a more preferred embodiment, the ethylene oxide is at the terminal portion of the molecule and the propylene oxide is in the center.

Abstract: Novel monocyclic terpene derivative of the formula: ##STR1## wherein R is hydrogen atom, trimethylsilyl group or 1-ethoxyethyl group, and novel intermediates therefor. The terpene derivative (I) is a useful intermediate for preparing Sarcophytol A having an anti-carcinogenesis promoter activity and an antitumor activity.

Abstract: The present invention relates to novel .alpha.-hydroxyacids of the general formula (I), to the process of preparing them and to the use thereof as intermediates allowing access to homologous lower aldehydes (such as prenal or citral) by oxidative decarboxylation.

Abstract: Disclosed are cationic lipids capable of facilitating transport of biologically active agents into cells, including the transfection of cells by therapeutic polynucleotides, the delivery of antiviral drugs, and the introduction of immunogenic peptides. The cationic lipids, comprising an ammonium group, have the general structure ##STR1## Also disclosed are adducts of these compounds comprising additional cationic sites that enhance the transfective or transport activity. Structure-activity correlations provide for the selection of preferred compounds to be synthesized for this purpose. Compositions disclosed for use of these cationic lipid include formulations for in vitro transfection and pharmaceutical formulations for parenteral and topical administration of therapeutic agents.

Abstract: The invention concerns 2-hydroxyalkenoic acids within a general formula ##STR1## where R' is chosen from: a. C.sub.w H.sub.2w,b. C.sub.y H.sub.2y-1, andc. C.sub.y H.sub.2y OZwhere Z is chosen from H, R" and (CH.sub.2).sub.n OR"R" is chosen from C.sub.m H.sub.2m+1 and (CH.sub.2).sub.n OC.sub.m H.sub.2m+1 ;w is an integer of from 1 to 25y is an integer of from 2 to 25m is an integer of from 1 to 4n is an integer of from 1 to 6Many compounds within the formula are novel and are claimed as such. The invention also provides a process for making the compounds, and compositions for topical application to human skin, hair or nails which contain compounds of the above formula and a cosmetically acceptable vehicle.

Abstract: A nutrient comprising fats and oils having superior digestibility and absorptivity are provided, which fats and oils are comprised of at least one triglyceride having fatty acids of C.sub.8 to C.sub.14 at the 2-position of the triglyceride and identical unsaturated acids of C.sub.18 or higher at both the 1- and 3-positions thereof. Examples of the unsaturated fatty acids of C.sub.18 or higher are linolic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid.

Abstract: Compounds of general formula (I), wherein R.sup.1 is hydrogen, C.sub.1-4 alkyl or a group of formula (II): --O(CH(R.sup.10)CH.sub.2 O).sub.n R.sup.20, R.sup.2 is hydrogen or a group of formula (III): --O(CH(R.sup.11)CH.sub.2 O).sub.m R.sup.21, R.sup.3 is a group of formula (IV): --(CH(R.sup.12)CH.sub.2 O).sub.p R.sup.22, and R.sup.4 is a group of formula (V): --(CH(R.sup.13)CH.sub.2 O).sub.r R.sup.23, where R.sup.10, R.sup.11, R.sup.12 and R.sup.13 each is hydrogen or CH.sub.3, R.sup.20 R.sup.21, R.sup.22 and R.sup.23 each is an acyl moiety of a polycarboxylic acid, and n, m, p and r each is an integer from 1 to 15; q is 1 or 2; with the provisos that if q is 2, then the 2 groups R.sup.1 may be the same or different and the 2 groups R.sup.2 may be the same or different; and, if one or more of the groups R.sup.20, R.sup. 21, R.sup.22, and R.sup.23 is an acyl moiety of a polycarboxylic acid group, then 0-3 of the remaining carboxy groups of the polycarboxylic acid form the acyl function(s) of a moiety R.sup.

Abstract: Ethyl (2E,4Z,7Z)-2,4,7-decatrienoate, a novel compound, is a useful perfuming ingredient capable of imparting odor notes of the pear, green, violet leaf type to the compositions and articles into which it is incorporated. It can also be advantageously used in a variety of flavoring compositions.

Abstract: Complexes of saponins from Centella asiatica, terminalia sp. and Terminalia sericea and relevant aglycons with phospholipids are described. The saponins may be asiaticoside, madecassicoside and sericoside. The molar ratio of phospholipids to saponins is from 0.5 to 2. The phospholipids are selected from the group consisting of soy lecithins, phospholipids from bovine or swine brain or cutis, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine in which the acyl groups can be the same or different and are mostly derived from palmitic, stearic, oleic, linoleic, linolenic acids. Pharmaceutical compositions and the method of treatment are also described.

Abstract: Glycerides of eicosapentaenoic acid (EPA) and other higher fatty acids, which contain high levels of EPA and docosahexaenoic acid. These glycerides are incorporated in oils and fats products such as margarine, shortening, mayonnaise, butter, dressing or edible oil.

Abstract: Fumaric acid derivatives of the formula ##STR1## wherein R.sub.1 is a hydrogen atom, a C.sub.1 -C.sub.8 alkyl group or a metallic cation, andR.sub.2 is a saturated or unsaturated aliphatic C.sub.6 -C.sub.24 alkyl group, psoralen-9-yl, retinyl, .alpha.-tocopheryl (vitamin E), calciferyl, corticosteroid-21-yl or monosaccharid-.omega.-yl; a group of fumaric acid derivatives based on glycerol, alkane diol or polyol molecules; and fumaric acid derivatives of the formula ##STR2## wherein n is an integer from to 30 to 260,R.sub.3 is a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group,R.sub.4 is one of the R.sub.3 groups and n is the number of molecule repetitions, processes for their production and compositions containing same are described. These compounds are useful as drugs for the treatment of cryptogenically-caused diseases and have antisporiatic as well as antimicrobial action.

Abstract: This invention provides a process for concentration and separation of an eicosapentaenoic acid ester comprising:(1) a step in which a solution, in a nonpolar solvent, of a mixture of fatty acid esters containing an eicosapentaenoic acid ester is allowed to contact with a zeolite, so as to allow said eicosapentaenoic ester to be adsorbed on said zeolite;(2) a step in which said zeolite is allowed to contact with a nonpolar solvent, so as to desorb impurities; and(3) a step in which said zeolite is allowed to contact with a polar solvent, so as to allow said eicosapentaenoic acid ester to be desorbed.This process makes it possible to obtain a highly pure eicosapentaenoic acid ester on a commercial scale.

Abstract: The present invention is directed to a novel internal mold release agent for use in a polyurethane(urea) RIM process. The release agent broadly consists of the transesterification product of a fatty acid and a lower alkyl acetoacetate.

Abstract: A process for the extraction of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acid esters from crude fish oils, by means of transesterification with ethanol and H.sub.2 SO.sub.4 and two-step molecular distillation.

Abstract: Novel fat mimetic compounds and their uses in food compositions are disclosed. These compounds comprise a backbone to which is attached one hydroxyl group acylated with a fatty acid, forming a pendant carboxy substituent (--O.sub.2 C--R', where R' is an aliphatic group having 1 to 30 carbons), and one carboxylic acid group esterified with a fatty alcohol, forming a pendant carboxylate substituent (--CO.sub.2 R', with R' as defined above).